Ipratropium bromide/salbutamol

From WikiProjectMed
(Redirected from Ipratropium/salbutamol)
Jump to navigation Jump to search
Ipratropium bromide/salbutamol
Combination of
Ipratropium bromideMuscarinic antagonist
SalbutamolShort-acting β2-adrenergic agonist
Names
Trade namesCombivent, DuoNeb, Breva, others
Clinical data
Pregnancy
category
  • US: C (Risk not ruled out)[1]
Routes of
use
Inhalation
Defined daily dosenot established[2]
External links
AHFS/Drugs.comProfessional Drug Facts
MedlinePlusa601063
Legal
License data
Legal status
  • AU: S3 (Pharmacist only)
  • UK: POM (Prescription only)
  • US: ℞-only
  (verify)

Ipratropium bromide/salbutamol, sold under the brand name Combivent among others, is a combination medication used to treat chronic obstructive pulmonary disease (COPD).[3][4] It contains ipratropium (an anticholinergic) and salbutamol (albuterol, a β2-adrenergic agonist).[3] It is taken by inhalation.[5]

Common side effects include sore throat, muscle cramps, and nausea.[3] Other side effects may include bronchospasm, allergic reactions, and upper respiratory tract infections.[3] Safety in pregnancy is unclear.[1] Each medication typically decreases bronchospasm and does so via different mechanisms.[3]

The combination was approved for medical use in the United States in 1996.[5] It is available as a generic medication.[4] Sixty doses in the United Kingdom costs the NHS about 18 £ as of 2019.[4] In the United States the wholesale cost of this amount is about US$9.50.[6] In 2017, it was the 172nd most commonly prescribed medication in the United States, with more than three million prescriptions.[7][8]

Dosage

The defined daily dose is not established[2]

Society and culture

Since Combivent contains a chlorofluorocarbon based propellant, it is being phased out in European Union countries. Chloroflourocarbons (CFC) are attributed to depletion of the ozone layer.

References

  1. 1.0 1.1 "Albuterol / ipratropium Use During Pregnancy". Drugs.com. Retrieved 19 April 2019.
  2. 2.0 2.1 "WHOCC - ATC/DDD Index". www.whocc.no. Retrieved 9 September 2020.
  3. 3.0 3.1 3.2 3.3 3.4 "DailyMed - ipratropium bromide and albuterol sulfate inhalant". dailymed.nlm.nih.gov. Retrieved 18 April 2019.
  4. 4.0 4.1 4.2 British national formulary : BNF 76 (76 ed.). Pharmaceutical Press. 2018. p. 247. ISBN 9780857113382.
  5. 5.0 5.1 "Ipratropium and Albuterol - FDA prescribing information, side effects and uses". Drugs.com. Retrieved 18 April 2019.
  6. "NADAC as of 2019-02-27". Centers for Medicare and Medicaid Services. Retrieved 3 March 2019.
  7. "The Top 300 of 2020". ClinCalc. Retrieved 11 April 2020.
  8. "Albuterol Sulfate; Ipratropium Bromide - Drug Usage Statistics". ClinCalc. Retrieved 11 April 2020.

External links

Identifiers:
  • DailyMed
  • Consumer Medication Information from PubMed
  • National Asthma Education and Prevention Program Expert Panel 3. Expert panel report 3: guidelines for the diagnosis and management of asthma. Bethesda (MD): National Institutes of Health. National Heart, Lung, and Blood Institute; 2007 Aug. NIH Publication No. 07-4051.